FANUY Quote, Financials, Valuation and Earnings

Kyocera has a net margin of -- compared to Fanuc's net margin of 7.38%. Fanuc's return on equity of -- beat Kyocera's return on equity of 3.11%.

Fanuc has a consensus price target of --, signalling downside risk potential of --. On the other hand Kyocera has an analysts' consensus of -- which suggests that it could grow by 11.73%. Given that Kyocera has higher upside potential than Fanuc, analysts believe Kyocera is more attractive than Fanuc.

Fanuc has a beta of 0.839, which suggesting that the stock is 16.102% less volatile than S&P 500. In comparison Kyocera has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.095%.

Fanuc has a quarterly dividend of $0.15 per share corresponding to a yield of 2.18%. Kyocera offers a yield of 3.25% to investors and pays a quarterly dividend of $0.17 per share. Fanuc pays -- of its earnings as a dividend. Kyocera pays out 73.91% of its earnings as a dividend. Kyocera's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fanuc quarterly revenues are --, which are smaller than Kyocera quarterly revenues of $3.2B. Fanuc's net income of -- is lower than Kyocera's net income of $236M. Notably, Fanuc's price-to-earnings ratio is -- while Kyocera's PE ratio is 20.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fanuc is 3.95x versus 1.03x for Kyocera. Usually stocks with elevated PS ratios are considered overvalued.

Nidec has a net margin of -- compared to Fanuc's net margin of -3.46%. Fanuc's return on equity of -- beat Nidec's return on equity of 8.22%.

Fanuc has a consensus price target of --, signalling downside risk potential of --. On the other hand Nidec has an analysts' consensus of -- which suggests that it could grow by 46.03%. Given that Nidec has higher upside potential than Fanuc, analysts believe Nidec is more attractive than Fanuc.

Fanuc has a beta of 0.839, which suggesting that the stock is 16.102% less volatile than S&P 500. In comparison Nidec has a beta of 1.080, suggesting its more volatile than the S&P 500 by 8.006%.

Fanuc has a quarterly dividend of $0.15 per share corresponding to a yield of 2.18%. Nidec offers a yield of 1.52% to investors and pays a quarterly dividend of $0.03 per share. Fanuc pays -- of its earnings as a dividend. Nidec pays out 32.08% of its earnings as a dividend. Nidec's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fanuc quarterly revenues are --, which are smaller than Nidec quarterly revenues of $4B. Fanuc's net income of -- is lower than Nidec's net income of -$138.3M. Notably, Fanuc's price-to-earnings ratio is -- while Nidec's PE ratio is 27.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fanuc is 3.95x versus 1.21x for Nidec. Usually stocks with elevated PS ratios are considered overvalued.

SBC Medical Group Holdings has a net margin of -- compared to Fanuc's net margin of 5.34%. Fanuc's return on equity of -- beat SBC Medical Group Holdings's return on equity of 25.89%.

Fanuc has a consensus price target of --, signalling downside risk potential of --. On the other hand SBC Medical Group Holdings has an analysts' consensus of -- which suggests that it could grow by 87.71%. Given that SBC Medical Group Holdings has higher upside potential than Fanuc, analysts believe SBC Medical Group Holdings is more attractive than Fanuc.

Fanuc has a beta of 0.839, which suggesting that the stock is 16.102% less volatile than S&P 500. In comparison SBC Medical Group Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fanuc has a quarterly dividend of $0.15 per share corresponding to a yield of 2.18%. SBC Medical Group Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fanuc pays -- of its earnings as a dividend. SBC Medical Group Holdings pays out -- of its earnings as a dividend.

Fanuc quarterly revenues are --, which are smaller than SBC Medical Group Holdings quarterly revenues of $53.1M. Fanuc's net income of -- is lower than SBC Medical Group Holdings's net income of $2.8M. Notably, Fanuc's price-to-earnings ratio is -- while SBC Medical Group Holdings's PE ratio is 13.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fanuc is 3.95x versus 2.70x for SBC Medical Group Holdings. Usually stocks with elevated PS ratios are considered overvalued.

SMC has a net margin of -- compared to Fanuc's net margin of 24.02%. Fanuc's return on equity of -- beat SMC's return on equity of 9.87%.

Fanuc has a consensus price target of --, signalling downside risk potential of --. On the other hand SMC has an analysts' consensus of -- which suggests that it could fall by --. Given that Fanuc has higher upside potential than SMC, analysts believe Fanuc is more attractive than SMC.

Fanuc has a beta of 0.839, which suggesting that the stock is 16.102% less volatile than S&P 500. In comparison SMC has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.808%.

Fanuc has a quarterly dividend of $0.15 per share corresponding to a yield of 2.18%. SMC offers a yield of 1.63% to investors and pays a quarterly dividend of $0.17 per share. Fanuc pays -- of its earnings as a dividend. SMC pays out 32.56% of its earnings as a dividend. SMC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fanuc quarterly revenues are --, which are smaller than SMC quarterly revenues of $1.3B. Fanuc's net income of -- is lower than SMC's net income of $312.4M. Notably, Fanuc's price-to-earnings ratio is -- while SMC's PE ratio is 21.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fanuc is 3.95x versus 4.85x for SMC. Usually stocks with elevated PS ratios are considered overvalued.